Odoribacter splanchnicus is a Gram-negative, obligate anaerobic bacterium belonging to the family Odoribacteraceae within the phylum Bacteroidota (formerly Bacteroidetes). It is a commensal resident of the human colon recognized primarily as a producer of short chain fatty acids — particularly butyrate and propionate — with complex and sometimes paradoxical associations across multiple disease states. Odoribacter is one of a small number of gut genera confirmed to show true opposing directionality between cancer and autoimmune disease microbiome signatures.
Classification and Ecology
Odoribacter is the sole genus in the family Odoribacteraceae, phylogenetically distinct from the major Bacteroidetes families (Bacteroidaceae, Prevotellaceae, Rikenellaceae). The primary clinical species is O. splanchnicus. As an obligate anaerobe within the Bacteroidetes phylum, it occupies a different ecological and metabolic niche from Firmicutes-derived butyrate producers like faecalibacterium prausnitzii and roseburia, reflecting the functional redundancy built into the gut's SCFA-producing capacity.
SCFA Production and Primary Gut Health Function
- O. splanchnicus ferments complex carbohydrates to produce butyrate, propionate, and succinate.
- Butyrate supports colonocyte energy metabolism (the primary fuel for colonocytes), gut barrier integrity through tight junction protein upregulation, and systemic immune regulation via HDAC inhibition and GPR109a signaling.
- Propionate contributes to hepatic gluconeogenesis regulation, appetite suppression via free fatty acid receptor signaling, and Treg differentiation.
- Anti-inflammatory mechanism: Odoribacter-derived butyrate specifically attenuates LPS-induced NF-κB activation, with butyrate from Odoribacter cited as a mechanism for lessening endotoxin-driven systemic inflammation [1]. This direct anti-inflammatory mechanism through NF-κB inhibition links Odoribacter's metabolic function to cardiovascular protection.
- Bile salt hydrolase activity contributes to secondary bile acid pool formation, influencing FXR and TGR5 signaling in the gut-liver axis.
Metal Dependencies
Iron dependency exists through iron-sulfur cluster enzymes in anaerobic fermentation pathways. As a Bacteroidetes member, Odoribacter has distinct iron utilization strategies compared to Firmicutes, relying on outer membrane iron transporters and TonB-dependent receptors rather than siderophores. The Bacteroidetes phylum has adapted to operate in the iron-limited colonic environment through high-affinity iron binding rather than siderophore secretion.
Opposing Directionality — The Cancer-Autoimmune Paradox
Odoribacter is one of only six genera confirmed with true opposite directionality in the systematic meta-analysis of cancer versus autoimmune microbiome signatures: increased in cancer studies and decreased in autoimmune cohorts [2].
This opposing pattern positions Odoribacter as a marker of divergent immune environments rather than a simple beneficial or harmful taxon:
- In autoimmune conditions (IBD, MS): its SCFA production would be immunosuppressive and anti-inflammatory — loss of this capacity disinhibits autoimmune inflammation.
- In cancer conditions (CRC): its enrichment may reflect a tumor microenvironment that favors SCFA-producing commensals, or alternatively, Odoribacter may contribute to the immunosuppressive tumor microenvironment through SCFA-mediated Treg induction.
This context-dependence is a fundamental challenge for microbiome therapeutics: the same organism is lost where its presence would help and enriched where its presence may facilitate immune evasion.
Cardiovascular Disease — Risk Despite SCFA Production
One of the most counter-intuitive findings in the Odoribacter literature:
CAD and MI Risk
Mendelian randomization identifies Odoribacter as a causal risk factor for coronary artery disease (OR=1.206) and myocardial infarction [3]. This contrasts with the expected cardioprotective role of butyrate producers, suggesting:
- Odoribacter's specific butyrate profile or co-metabolites may have distinct cardiovascular effects vs. other butyrate producers
- The MR finding may reflect bacterial metabolites beyond SCFA (bile acid metabolites, succinate, or other Bacteroidetes-specific products) contributing to cardiovascular risk
- Confounding by dietary patterns that simultaneously enrich Odoribacter and cardiovascular risk factors
Hypertension
Depleted in hypertension — listed among butyrate-producing commensals reduced in hypertensive patients [4]. The protective vs. risk-associated cardiovascular signals likely reflect different disease states and mechanisms.
Viral Myocarditis
Depleted alongside other commensal anaerobes in viral myocarditis (CVB3 model), suggesting that the metabolic disruption of acute viral infection displaces Odoribacter from its niche [5].
Cancer Associations
Pancreatic Cancer — Causal Risk Factor
MR analysis identifies Odoribacter (OR=1.899, p=0.011) as a causal risk factor for pancreatic cancer [6]. The proposed mechanism involves Odoribacter's role in bile acid transformation — the altered bile acid pool in the duodenum and pancreatic duct may create a pro-carcinogenic environment. This represents the second major cancer risk association alongside CRC enrichment.
Pancreatic Ductal Adenocarcinoma (PDAC) — Discriminating Biomarker
Odoribacter splanchnicus is among the top discriminating biomarkers for PDAC vs. healthy controls and autoimmune pancreatitis, achieving AUC 88.89–90.74% in shotgun metagenomics analysis [7]. Its fecal abundance is decreased in PDAC, alongside Eubacterium rectale and E. ventricosum, with significantly reduced gut butyrate content in PDAC — establishing that PDAC creates a SCFA-deficient gut environment.
Colorectal Cancer
Found in tissue-associated bacterial communities of rectal carcinoma [8] and altered following fecal microbiota transplantation in CRC progression models [9], consistent with the opposing-signature enrichment in CRC.
IBD and Autoimmune Disease — Depletion
Inflammatory Bowel Disease
Implicated in extraintestinal manifestations of inflammatory bowel disease through MR analyses, suggesting that Odoribacter's metabolic products have systemic effects extending beyond the gut lumen [10]. Its depletion in IBD is consistent with the broader loss of SCFA-producing Bacteroidetes commensals.
Multiple Sclerosis
Depleted in MS patients — specifically, decreased Barnesiellaceae, Barnesiella, and Odoribacter in the bacterial microbiome, while Eggerthellaceae and Blautia increase [11]. The MS gut microbiome also shows an increased fungal-to-bacterial richness ratio, suggesting that Odoribacter depletion may facilitate fungal expansion through reduced butyrate production.
Metformin Treatment Response Prediction
Odoribacter abundance at baseline predicts metformin treatment response in type 2 diabetes: enriched in Responders along with Enterococcus faecium, Lactococcus lactis, and Dialister [12]. This predictive value positions Odoribacter as a potential baseline biomarker for metabolic therapy selection, adding clinical utility beyond its disease association roles.
Context-Dependent Effects — Interpretive Framework
The wide spectrum of Odoribacter associations — protective in some cardiovascular and autoimmune contexts, risk-associated in CAD and pancreatic cancer — reflects:
- Metabolite diversity: Odoribacter produces butyrate, propionate, AND succinate. Different metabolites dominate under different conditions. Succinate at high levels is pro-inflammatory (SUCNR1 signaling); the balance shifts by substrate availability and microbial community context.
- Bile acid metabolism: Its bile salt hydrolase activity generates secondary bile acids that have complex context-dependent effects on epithelial proliferation vs. immune modulation.
- Disease-specific immune framing: In autoimmune disease, SCFA production provides needed immunosuppression (protective). In cancer, the same immunosuppression facilitates tumor immune evasion (harmful). The bacterium hasn't changed; the host immune context has.
What Wikipedia Doesn't Cover
Wikipedia lacks an Odoribacter entry. This page provides: the opposing-directionality cancer-autoimmune paradox as one of 6 confirmed genera with this signature; the specific NF-κB inhibition mechanism for cardiovascular protection; MR-established CAD causal risk (OR=1.206) despite SCFA production; PDAC biomarker status with AUC data; metformin response prediction; and pancreatic cancer causal risk (OR=1.899) with bile acid transformation as proposed mechanism.
Key Sources
- [2] — opposing directionality; one of 6 genera with true opposite signatures
- [3] — MR CAD risk (OR=1.206)
- [6] — PC causal risk (OR=1.899)
- [7] — PDAC biomarker AUC 88-91%
- [12] — metformin response predictor
Cross-References
- short chain fatty acids — produces butyrate, propionate, and succinate
- cardiovascular disease — NF-κB inhibition via butyrate; MR evidence as CAD risk factor despite SCFA
- colorectal cancer — enriched in cancer cohorts; opposing-signature analysis
- pancreatic cancer — MR causal risk factor; PDAC fecal biomarker with AUC 88-91%
- inflammatory bowel disease — depleted in autoimmune conditions; MR extraintestinal manifestations
- multiple sclerosis — depleted; co-depletion with Barnesiella; fungal expansion implications
- dysbiosis — opposite-directionality genus bridging cancer and autoimmune signatures
- bile acid metabolism — bile salt hydrolase activity; bile acid transformation linked to PC risk
- iron — Fe-S dependent anaerobic fermentation; TonB-dependent iron transport
- candida albicans — reduced butyrate from Odoribacter depletion may facilitate fungal expansion in MS